MeltArray反应鉴定并定量氟喹诺酮耐药结核分枝杆菌gyrA变异
研究建立MeltArray MTB/FQs多重PCR方法,可在单反应3小时内检测gyrA-QRDR的11种突变并定量突变比例,LOD为50拷贝/反应。442份培养样本与表型药敏比较灵敏度95.23%、特异度99.32%;121对痰-培养样本中痰灵敏度90.32%、培养95.24%,特异度均100%。
要点
- MeltArray可在3小时内单反应鉴定11种gyrA-QRDR突变并定量突变比例。
- 与pAST比较,442份培养样本灵敏度95.23%、特异度99.32%。
- 可识别低至5%的突变混合比例,助力异质性耐药检测。
核心结论
- MeltArray MTB/FQs为常规氟喹诺酮耐药监测提供升级替代方案,可早期检测并精准管理pre-XDR-TB。
研究设计与样本
- 建立多重PCR方法MeltArray MTB/FQs,采用多项式回归算法公式定量突变比例;评估442份培养样本、121对痰-培养样本和285份痰样本。
主要发现
- 442份培养样本与pAST比较灵敏度95.23%、特异度99.32%。
- 121对痰-培养样本中痰灵敏度90.32%、培养95.24%,特异度均100%。
- 285份痰样本与MeltPro MTB/FQs试剂盒比较PPA 93.75%、NPA 98.10%。
- MUT%预测公式与ddPCR比较,训练、验证和测试数据集准确率分别为88.00%、88.89%、83.33%。
关键数值与推荐
- LOD为50拷贝/反应,可识别含5%突变gDNA、50至50,000拷贝/反应的混合物。
- 3小时内单反应完成突变鉴定与定量。
临床怎么用
- 可用于痰标本直接、不依赖培养的氟喹诺酮耐药检测,识别低比例异质性耐药。
局限性
- MeltArray判为突变而pAST判敏感或MeltPro判野生型的样本均经Sanger测序和ddPCR确认,提示其他方法可能存在漏检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fluoroquinolones (FQs) resistance in Mycobacterium tuberculosis (MTB), primarily driven by mutations in the quinolone resistance-determining region (QRDR) of gyrA, poses a major concern in treating for multidrug-resistant tuberculosis (MDR-TB). These QRDR mutations are known to confer varying levels of resistance, leading to differences in treatment outcomes. Here, we introduced the MeltArray MTB/FQs assay, a multiplex PCR method that detected 11 gyrA-QRDR mutations and quantified their fractions via a polynomial regression algorithm-based formula, enabling mutation identification and quantification within 3 h in one reaction. This assay, with a limit of detection (LOD) of 50 copies/reaction, could identify mixtures containing 5% mutant gDNA across 50 to 50,000 copies/reaction. Clinical evaluation of 442 culture samples displayed 95.23% sensitivity and 99.32% specificity compared with phenotypic antimicrobial susceptibility testing (pAST). Evaluation of 121 paired sputum-culture samples revealed sensitivities of 90.32% in sputum samples and 95.24% in culture samples, both with specificities of 100%, when compared with pAST. Further evaluation of 285 sputum samples showed 93.75% positive percent agreement (PPA) and 98.10% negative percent agreement (NPA) in comparison with the MeltPro MTB/FQs kit (Zeesan Biotech, China). All mutant samples identified by MeltArray MTB/FQs but classified as susceptible by pAST or as wild type by MeltPro MTB/FQs were confirmed through Sanger sequencing and droplet digital PCR (ddPCR). The formula for predicting mutation fraction (MUT%) showed accuracy rates of 88.00%, 88.89%, and 83.33% in the training, validation, and test data sets, respectively, when compared with ddPCR results. Overall, MeltArray MTB/FQs assay offers an upgraded alternative for routine FQs resistance monitoring.IMPORTANCERising FQs resistance has driven the spread of pre-extensively drug-resistant tuberculosis (pre-XDR-TB), challenging global tuberculosis (TB) control efforts. Conventional molecular assays for FQs resistance often cannot distinguish between low-level and high-level resistance mutations or detect low-fraction heteroresistant populations. In this study, we established a MeltArray MTB/FQs assay that can identify all the 11 critical mutations in the gyrA-QRDR with a LOD of 50 copies/reaction, enabling direct, culture-independent analysis of sputum samples. By using an algorithm to quantify mutations at levels as low as 5% in mixtures, MeltArray achieved both mutation identification and quantification within 3 h in a reaction, thus providing a powerful tool for early detection and precise management of pre-XDR-TB.
引用
- Tu C, Su B, Xiong Y, et al. Identification and quantification of gyrA variants in fluoroquinolone-resistant Mycobacterium tuberculosis in a MeltArray reaction. J Clin Microbiol. 2025. PMID: 40459255. doi:10.1128/jcm.00146-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。